05 Nov 2012 Posted in News Release By Press Office
Colette, who comes from Northern Ireland, has a long history of working in senior roles in the pharmaceutical industry. Her career includes eight years at Glaxo in their Public Affairs and Communications team, where she left as Head of Communications.
Colette also spent nine years at Pfizer in various capacities – Head of Communications, Corporate Affairs Director and Head of Public Affairs and Policy for Pfizer Europe. In her last role at Pfizer she led a team of 30, responsible for corporate reputation, policy development, government relations and communications strategy, as well as overseeing the work of a significant corporate affairs team across the EU.
Colette will be supported in her work by Marion Laverty who will provide office management. Marion will also help identify, establish and develop productive relationships with key opinion leaders and decision makers in Northern Ireland.
Commenting Stephen Whitehead, Chief Executive of the ABPI, said:
"I am delighted that we have secured such a strong talent in Colette to build and lead the ABPI in Northern Ireland. The ABPI believes that Northern Ireland represents a significant opportunity for the bio-pharmaceutical industry in terms of the growing life science agenda, arising from world class capability at Queen's University Belfast, the University of Ulster and the Science Park. Our partnership-based approach will seek to engage all stakeholders in supporting healthcare professionals to effectively utilise innovative medicines and improve patient health.
"Northern Ireland has a better record of using innovative medicines and consequently in several critical areas has better patient outcomes than England, most notably in certain cancers and forms of heart disease.
"Colette will work closely with our members in Northern Ireland whilst drawing on expertise in the London office."
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.